Brain Injuries, Acute — Signal Analysis for Neurocritical Patients
Citation(s)
Christopher Torrence and Gilbert P Compo. (1998 Jan) A practical guide to wavelet analysis. Bulletin of the American Meteorological Society 79(1):61-78.
Diederik P Kingma and Jimmy Lei Ba. Adam: A method for stochastic optimization. Conference paper at ICLR 2015.
LeCun Y, Bengio Y, Hinton G Deep learning. Nature. 2015 May 28;521(7553):436-44. doi: 10.1038/nature14539. Review.
Michael Unser and Akram Aldroubi (1996 Apr) A review of wavelets in biomedical applications. Proceedings of the IEEE 84(4): 626-638.
Min S, Lee B, Yoon S Deep learning in bioinformatics. Brief Bioinform. 2017 Sep 1;18(5):851-869. doi: 10.1093/bib/bbw068. Review.
Theis, Fabian & Meyer-Base, Anke (2010). Biomedical Signal Analysis - Contemporary Methods and Applications. Biomedical Signal Analysis: Contemporary Methods and Applications.
Yi Mao, Wenlin Chen, Yixin Chen, Chenyang Lu, Marin Kollef, and Thomas Bailey (2012) An integrated data mining approach to real-time clinical monitoring and deterioration warning. Proceedings of the 18th ACM SIGKDD international conference on Knowledge discovery and data mining Pages 1140-1148. doi>10.1145/2339530.2339709
Analysis of Physiological Signals From Neurocritical Patients in Intensive Care Units Using Wavelet Transform and Deep Learning
Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.
Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.
Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.
Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.
Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.
